Banner MD Anderson Cancer Center
RecruitingGilbert, Arizona, 85234, United States
Study team contact · shared across sites
CLINICAL STUDY · NCT06162221
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
RecruitingPhase 1 / Phase 2Interventional
Sponsored by Revolution Medicines, Inc.
- Condition
- Non-Small Cell Lung Cancer, NSCLC, KRAS, NRAS, HRAS-mutated NSCLC, KRAS G12C-mutated Solid Tumors, Lung Cancer, Lung Cancer Stage IV, Advanced Solid Tumor, Cancer, RAS G12D-mutated NSCLC
- Study locations
- 98 reported sites
- Study updated
- 19 Oct 2026
- Source
- ClinicalTrials.gov
Overall study status is shown above. Individual hospitals may have a different recruitment status.
THE STUDY
About this study
The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors as a monotherapy or combined with Standard(s) of Care (SOC) or with each other.
The first four subprotocols include the following:
Subprotocol A: RMC-6291 +/- RMC-6236 + SOC Subprotocol B: RMC-6236 + SOC Subprotocol C: RMC-9805 +/- RMC-6236 + SOC Subprotocol D: RMC-9805
The first four subprotocols include the following:
Subprotocol A: RMC-6291 +/- RMC-6236 + SOC Subprotocol B: RMC-6236 + SOC Subprotocol C: RMC-9805 +/- RMC-6236 + SOC Subprotocol D: RMC-9805
Full official title
A Platform Study of RAS(ON) Inhibitors in Patients With RAS-Mutated Non-Small Cell Lung Cancer (NSCLC)
Detailed description
The platform study design allows combinations of RAS(ON) inhibitors with other anticancer agents or as a monotherapy to be evaluated in patients with RAS-mutated solid tumors with a focus on NSCLC.
This is an open-label platform Phase 1b/2 study to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard of Care (SOC), or as a monotherapy and to define the Recommended Phase 2 Dose and Schedule (RP2DS). Enrollment of patients with KRAS or RAS mutations will be specified in each subprotocol.
Subprotocol A is an open-label, multicenter, Phase 1b/2 study of RMC-6291, with or without RMC-6236, in combination with pembrolizumab, with or without chemotherapy, in patients with KRAS G12C-mutated advanced solid tumors.
Subprotocol B is an open-label, multicenter, Phase1b/2 study of RMC-6236 in combination with pembrolizumab, with or without chemotherapy, in patients with RAS-mutated non-small cell lung cancer (NSCLC)
Subprotocol C is an open-label, multicenter, Phase1b/2 study of RMC-9805 with or without RMC-6236, in combination with other anticancer agents, in patients with RAS G12D-mutated non-small cell lung cancer (NSCLC)
Subprotocol D is a Phase 2, Open-label, Multicenter Study of Zoldonrasib (RMC-9805) in Previously Treated Patients with RAS G12D-Mutant Non-Small Cell Lung Cancer (NSCLC)
Subprotocols A, B, and C consist of two parts: Part 1 - Dose Exploration and Part 2 - Dose Expansion. Subprotocol D consists of only one part.
This is an open-label platform Phase 1b/2 study to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard of Care (SOC), or as a monotherapy and to define the Recommended Phase 2 Dose and Schedule (RP2DS). Enrollment of patients with KRAS or RAS mutations will be specified in each subprotocol.
Subprotocol A is an open-label, multicenter, Phase 1b/2 study of RMC-6291, with or without RMC-6236, in combination with pembrolizumab, with or without chemotherapy, in patients with KRAS G12C-mutated advanced solid tumors.
Subprotocol B is an open-label, multicenter, Phase1b/2 study of RMC-6236 in combination with pembrolizumab, with or without chemotherapy, in patients with RAS-mutated non-small cell lung cancer (NSCLC)
Subprotocol C is an open-label, multicenter, Phase1b/2 study of RMC-9805 with or without RMC-6236, in combination with other anticancer agents, in patients with RAS G12D-mutated non-small cell lung cancer (NSCLC)
Subprotocol D is a Phase 2, Open-label, Multicenter Study of Zoldonrasib (RMC-9805) in Previously Treated Patients with RAS G12D-Mutant Non-Small Cell Lung Cancer (NSCLC)
Subprotocols A, B, and C consist of two parts: Part 1 - Dose Exploration and Part 2 - Dose Expansion. Subprotocol D consists of only one part.
PARTICIPATION
Who may participate
- Minimum age
- 18 Years
- Maximum age
- Not reported
- Sex eligibility
- All sexes
- Healthy volunteers
- Not accepted
Only the study team can confirm eligibility. The registry criteria below are not a medical recommendation.
Full inclusion and exclusion criteria
Inclusion criteria:
All Patients (unless otherwise noted):
* ≥ 18 years of age
* ECOG PS is 0 to 1
* Adequate organ function as outlined by the study
* Received prior standard therapy appropriate for tumor type and stage
* Must have pathologically documented, locally advanced or metastatic KRAS G12C-mutated solid tumor malignancy (not amenable to curative surgery) (Subprotocol A)
* Must have pathologically documented, locally advanced or metastatic RAS-mutated NSCLC (Subprotocol B)
* Must have pathologically documented, locally advanced or metastatic RAS G12D-mutated NSCLC (Subprotocol C and Subprotocol D)
Exclusion criteria:
All Patients:
* Primary central nervous system (CNS) tumors
* Impaired gastrointestinal (GI) function that may significantly alter the absorption of RMC drugs
* Major surgery \< 28 days of first dose
* Active or history of interstitial lung disease (ILD) or pneumonitis requiring steroids
Other inclusion/exclusion criteria may apply.
All Patients (unless otherwise noted):
* ≥ 18 years of age
* ECOG PS is 0 to 1
* Adequate organ function as outlined by the study
* Received prior standard therapy appropriate for tumor type and stage
* Must have pathologically documented, locally advanced or metastatic KRAS G12C-mutated solid tumor malignancy (not amenable to curative surgery) (Subprotocol A)
* Must have pathologically documented, locally advanced or metastatic RAS-mutated NSCLC (Subprotocol B)
* Must have pathologically documented, locally advanced or metastatic RAS G12D-mutated NSCLC (Subprotocol C and Subprotocol D)
Exclusion criteria:
All Patients:
* Primary central nervous system (CNS) tumors
* Impaired gastrointestinal (GI) function that may significantly alter the absorption of RMC drugs
* Major surgery \< 28 days of first dose
* Active or history of interstitial lung disease (ILD) or pneumonitis requiring steroids
Other inclusion/exclusion criteria may apply.
NEAR YOU
Study locations worldwide
98 sitesCheck the individual site’s status and contact the listed study team for current availability.
98 sites shown
City of Hope - Duarte
Active, not recruitingDuarte, California, 91010, United States
Study team contact · shared across sites
City of Hope - Lennar
Active, not recruitingIrvine, California, 92618, United States
Study team contact · shared across sites
University of California Los Angeles
Active, not recruitingLos Angeles, California, 90095, United States
Study team contact · shared across sites
UC Davis, Davis Comprehensive Cancer Center
RecruitingSacramento, California, 95817, United States
Site contacts (1)
University of California, San Diego Moores Cancer Center
RecruitingSan Diego, California, 92037, United States
Site contacts (1)
UCSF Medical Center - Mission Bay
RecruitingSan Francisco, California, 94158, United States
Site contacts (1)
Stanford University - Stanford Cancer Institute
RecruitingStanford, California, 94305, United States
Site contacts (1)
Kaiser Permanente
Active, not recruitingVallejo, California, 94589, United States
Study team contact · shared across sites
Georgetown University Medical Center
RecruitingWashington D.C., District of Columbia, 20007, United States
Site contacts (1)
Boca Raton Clinical Research Associates
RecruitingPlantation, Florida, 33322, United States
Site contacts (1)
Cancer Specialists of North Florida
Active, not recruitingSaint Augustine, Florida, 32086, United States
Study team contact · shared across sites
H Lee Moffitt Cancer Center and Research Institute
RecruitingTampa, Florida, 33612, United States
Site contacts (1)
Dana Farber Cancer Institute
RecruitingBoston, Massachusetts, 02215, United States
Site contacts (1)
Henry Ford Cancer - Detroit (Brigitte Harris Cancer Pavilion)
Active, not recruitingDetroit, Michigan, 48202, United States
Study team contact · shared across sites
Intermountain Health - St. Vincent Frontier Cancer Center
Active, not recruitingBillings, Montana, 59102, United States
Study team contact · shared across sites
Nebraska Cancer Specialist
RecruitingGrand Island, Nebraska, 68803, United States
Study team contact · shared across sites
New York University Langone Health
RecruitingNew York, New York, 10016, United States
Site contacts (1)
Icahn School of Medicine at Mount Sinai
Active, not recruitingNew York, New York, 10029, United States
Study team contact · shared across sites
Columbia University Medical Center
RecruitingNew York, New York, 10032, United States
Site contacts (1)
Clinical Research Alliance
Active, not recruitingWestbury, New York, 11590, United States
Study team contact · shared across sites
University Hospitals Cleveland Medical Center
RecruitingCleveland, Ohio, 44106, United States
Site contacts (1)
Name not reportedContactPhone: 216-844-3951
UPMC Hillman Cancer Center
RecruitingPittsburgh, Pennsylvania, 15232, United States
Site contacts (1)
Name not reportedContactEmail: iddcreferrals@upmc.edu
Baptist Medical Center
RecruitingMemphis, Tennessee, 38120, United States
Study team contact · shared across sites
Tennessee Oncology
RecruitingNashville, Tennessee, 37203, United States
Study team contact · shared across sites
The University of Texas MD Anderson Cancer Center
RecruitingHouston, Texas, 77030, United States
Site contacts (1)
NEXT Oncology Dallas
RecruitingIrving, Texas, 75039, United States
Site contacts (1)
NEXT Oncology Virginia
RecruitingFairfax, Virginia, 22031, United States
Site contacts (1)
Fred Hutchinson Cancer Research Center
Active, not recruitingSeattle, Washington, 98109, United States
Study team contact · shared across sites
Chris O'Brien Lifehouse Hosptial
Active, not recruitingCamperdown, New South Wales, 2050, Australia
Study team contact · shared across sites
Liverpool Hospital
Active, not recruitingLiverpool, New South Wales, 2170, Australia
Study team contact · shared across sites
Royal North Shore Hospital
Active, not recruitingSt Leonards, New South Wales, 2065, Australia
Study team contact · shared across sites
Monash Health
Active, not recruitingClayton, Victoria, 3168, Australia
Study team contact · shared across sites
Linear Clinical Research
Active, not recruitingNedlands, Western Australia, 6009, Australia
Study team contact · shared across sites
Universitätsklinikum St. Pölten
Active, not recruitingSankt Pölten, Austria, 3100, Austria
Study team contact · shared across sites
Wiener Gesundheitsverbund - Klinik Floridsdorf
Active, not recruitingVienna, 1210, Austria
Study team contact · shared across sites
Nemocnice AGEL Novy Jicin a.s
Active, not recruitingNový Jičín, Czech Republic, 741 01, Czechia
Study team contact · shared across sites
Rigshospitalet
RecruitingCopenhagen, 2100, Denmark
Study team contact · shared across sites
Odense University Hospital, Department of Oncology
RecruitingOdense, 5000, Denmark
Study team contact · shared across sites
Hospices Civils de Lyon - Hôpital Louis Pradel
RecruitingBron, Auvergne-Rhône-Alpes, 69500, France
Site contacts (1)
Centre Georges François Leclerc
RecruitingDijon, Bourgogne-Franche-Comté, 21079, France
Site contacts (1)
CHU de Lille Institut Cœur Poumon
RecruitingLille, Hauts-de-France, 59037, France
Site contacts (1)
CHU de Nantes
Active, not recruitingNantes, Hauts-de-France, 44093, France
Study team contact · shared across sites
EDOG - Institut Bergonié
RecruitingBordeaux, New Aquitaine, 33000, France
Site contacts (1)
Institut de Cancerologie de Ouest (ICO) - Angers
RecruitingAngers, 49055, France
Study team contact · shared across sites
Ambroise-Paré Hospital
Active, not recruitingBoulogne, 92104, France
Study team contact · shared across sites
Centre François Baclesse
RecruitingCaen, 14076, France
Site contacts (1)
Hôpital Cochin
RecruitingParis, 75014, France
Study team contact · shared across sites
Hopital Tenon - AP-HP
Active, not recruitingParis, 75020, France
Study team contact · shared across sites
Hopital Foch
Active, not recruitingSuresnes, 92150, France
Study team contact · shared across sites
Oncopole Claudius Regaud
RecruitingToulouse, 31059, France
Site contacts (1)
Institut Gustave Roussy
RecruitingVillejuif, 94805, France
Site contacts (1)
Institut Curie
RecruitingParis, Île-de-France Region, 75005, France
Site contacts (1)
Charite-Universitaetsmedizin Berlin - Campus Charite Mitte
RecruitingBerlin, 12203, Germany
Site contacts (1)
Uniklinik Köln
RecruitingCologne, 50937, Germany
Site contacts (1)
Name not reportedContactEmail: lungenkrebs@uk-koeln.de
Universitätsklinikum Carl Gustav Carus an der TU Dresden
RecruitingDresden, 01307, Germany
Site contacts (1)
Universitätsklinikum Frankfurt
RecruitingFrankfurt am Main, 60590, Germany
Site contacts (1)
Thoraxklinik Heidelberg gGmbH - Universitätsklinikum Heidelberg
RecruitingHeidelberg, 69126, Germany
Site contacts (1)
Name not reportedContactEmail: Studienkoordination-Onkologie.THOR@med.uni-heidelberg.de
Lungenfachklinik Immenhausen
Active, not recruitingImmenhausen, 34376, Germany
Study team contact · shared across sites
Krankenhaus Bethanien Moers
Active, not recruitingMoers, 47441, Germany
Study team contact · shared across sites
Henry Dunant Hospital Center
Active, not recruitingAthens, 115 26, Greece
Study team contact · shared across sites
Thoracic General Hospital of Athens "I SOTIRIA"
Active, not recruitingAthens, 11527, Greece
Study team contact · shared across sites
General Hospital of Thessaloniki
Active, not recruitingThessaloniki, 570 10, Greece
Study team contact · shared across sites
Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l
RecruitingMeldola, Emilia-Romagna, 47014, Italy
Site contacts (1)
Oriana NanniContactEmail: oriana.nanni@irst.emr.it
Fondazione IRCCS Istituto Nazionale dei tumori
RecruitingMilan, 20133, Italy
Study team contact · shared across sites
Instituto Europeo Di Oncologia
Active, not recruitingMilan, 20141, Italy
Study team contact · shared across sites
ASST Grande Ospedale Metropolitano Niguarda
Active, not recruitingMilan, 20162, Italy
Study team contact · shared across sites
A.O.U. San Luigi Gonzaga-Orbassano - SCDU Oncologia Medica
Active, not recruitingOrbassano, 10043, Italy
Study team contact · shared across sites
Ospedale Santa Maria Delle Croci
RecruitingRavenna, 48121, Italy
Site contacts (1)
IRCCS Instituto Nazionale tumori Ragina Elena
Active, not recruitingRome, 00144, Italy
Study team contact · shared across sites
Fondazione Policlinico Universitario A Gemelli-Rome
Active, not recruitingRome, 00168, Italy
Study team contact · shared across sites
The Netherlands Cancer Institute (NKI)
RecruitingAmsterdam, 1066, Netherlands
Site contacts (1)
University Medical Centre Groningen
Active, not recruitingGroningen, 9713, Netherlands
Study team contact · shared across sites
Leiden University Medical Center
RecruitingLeiden, 2333 ZA, Netherlands
Study team contact · shared across sites
University Medical Center Utrecht
RecruitingUtrecht, 3584, Netherlands
Site contacts (1)
Samsung Medical Center
Active, not recruitingSeoul, Gangnam-gu, 06351, South Korea
Study team contact · shared across sites
National Cancer Center
Active, not recruitingGoyang-si, Gyeonggi-do, 10408, South Korea
Study team contact · shared across sites
Seoul National University Bundang Hospital
Active, not recruitingSeongnam-si, Gyeonggido, 13620, South Korea
Study team contact · shared across sites
Seoul St. Mary's Hospital, The Catholic University of Korea
Active, not recruitingSeoul, Seocho-gu, 06591, South Korea
Study team contact · shared across sites
Severance Hospital
Active, not recruitingSeoul, Seodaemun-Gu, 03722, South Korea
Study team contact · shared across sites
Hospital Clinico San Carlos
RecruitingMadrid, Madrid, 28040, Spain
Site contacts (1)
Hospital Universitario 12 de Octubre
RecruitingMadrid, Madrid, 28041, Spain
Site contacts (1)
Name not reportedContactEmail: oncologia.imas12@h12o.es
Clinica Universidad de Navarra
RecruitingPamplona, Navarre, 31008, Spain
Site contacts (1)
Hospital Universitari i Politecnic La Fe de Valencia
RecruitingValencia, Valencia, 46026, Spain
Study team contact · shared across sites
Complejo Hospitalario Universitario A Coruña
RecruitingA Coruña, 15006, Spain
Site contacts (1)
Hospital Universitari Vall D' Hebron
RecruitingBarcelona, 08035, Spain
Study team contact · shared across sites
ICO Badalona - H.U. Germans Trias i Pujol
Active, not recruitingBarcelona, 08916, Spain
Study team contact · shared across sites
Hospital Universitario Ramon y Cajal
RecruitingMadrid, 28034, Spain
Site contacts (1)
Maria Eugenia OlmedoContactPhone: 34-913-369-159
Hospital Universitario Fundacion Jimenez Diaz
RecruitingMadrid, 28040, Spain
Site contacts (1)
Hospital Universitario Quironsalud - NEXT Oncology, Madrid
Active, not recruitingMadrid, 28223, Spain
Study team contact · shared across sites
Hospital Regional Universitario de Malaga - Hospital Civil
RecruitingMálaga, 29011, Spain
Site contacts (1)
Hospital Universitario Virgen del Rocio - PPDS
RecruitingSeville, 41014, Spain
Site contacts (1)
Fundacion Instituto Valenciano de Oncologia
RecruitingValencia, 46009, Spain
Site contacts (1)
Taipei Municipal Wanfang Hospital
Active, not recruitingTaipei, Wenshan Dist, 116, Taiwan
Study team contact · shared across sites
Kaohsiung Medical University Chung-Ho Memorial Hospital
Active, not recruitingKaohsiung City, 807, Taiwan
Study team contact · shared across sites
Taichung Veterans General Hospital
Active, not recruitingTaichung, 40705, Taiwan
Study team contact · shared across sites
Chi Mei Hospital, Liouying
Active, not recruitingTainan, 73657, Taiwan
Study team contact · shared across sites
Taipei Veterans General Hospital
Active, not recruitingTaipei, 11217, Taiwan
Study team contact · shared across sites
No centres match this search. Try another hospital, city, state or country.
WHAT IS BEING STUDIED
Treatments and study groups
Interventions
RMC-6291
Oral tablet
Study groups: Subprotocol A: KRAS G12C-Mutated Solid Tumors
RMC-6236
Oral tablet
Study groups: Subprotocol A: KRAS G12C-Mutated Solid Tumors, Subprotocol B: RAS-mutated NSCLC, Subprotocol C: RAS G12D-mutated NSCLC
Pembrolizumab
IV Infusion
Study groups: Subprotocol A: KRAS G12C-Mutated Solid Tumors, Subprotocol B: RAS-mutated NSCLC, Subprotocol C: RAS G12D-mutated NSCLC
Cisplatin
IV Infusion
Study groups: Subprotocol A: KRAS G12C-Mutated Solid Tumors, Subprotocol B: RAS-mutated NSCLC, Subprotocol C: RAS G12D-mutated NSCLC
Carboplatin
IV Infusion
Study groups: Subprotocol A: KRAS G12C-Mutated Solid Tumors, Subprotocol B: RAS-mutated NSCLC, Subprotocol C: RAS G12D-mutated NSCLC
Pemetrexed
IV infusion
Study groups: Subprotocol A: KRAS G12C-Mutated Solid Tumors, Subprotocol B: RAS-mutated NSCLC, Subprotocol C: RAS G12D-mutated NSCLC
RMC-9805
Oral Tablet
Study groups: Subprotocol C: RAS G12D-mutated NSCLC, Subprotocol D: RAS G12D-mutated NSCLC
Study groups
Subprotocol A: KRAS G12C-Mutated Solid Tumors
RMC-6291 (BID), RMC-6236 (QD), and Pembrolizumab (Q3W) with or without Chemotherapy (Q3W)
Interventions: Drug: RMC-6291, Drug: RMC-6236, Drug: Pembrolizumab, Drug: Cisplatin, Drug: Carboplatin, Drug: Pemetrexed
Subprotocol B: RAS-mutated NSCLC
RMC-6236 (QD) and Pembrolizumab (Q3W) with or without Chemotherapy (Q3W)
Interventions: Drug: RMC-6236, Drug: Pembrolizumab, Drug: Cisplatin, Drug: Carboplatin, Drug: Pemetrexed
Subprotocol C: RAS G12D-mutated NSCLC
RMC-9805 (QD or BID), RMC-6236 (QD), and Pembrolizumab (Q3W) with or without Chemotherapy (Q3W).
Interventions: Drug: RMC-6236, Drug: Pembrolizumab, Drug: Cisplatin, Drug: Carboplatin, Drug: Pemetrexed, Drug: RMC-9805
Subprotocol D: RAS G12D-mutated NSCLC
RMC-9805 (QD)
Interventions: Drug: RMC-9805
RESEARCH DETAILS
Study design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Primary purpose
- Treatment
- Allocation
- Non randomized
- Study model
- Parallel
- Masking
- None (open label)
- Enrolment
- 616 participants · Estimated
TIMELINE & MEASURES
Dates and outcomes
- Study started
- 18 Jan 2024 · Actual
- Primary completion
- Jun 2027 · Estimated
- Study completion
- Dec 2028 · Estimated
- First registered
- 8 Dec 2023 · Actual
- Last registry update
- 19 Oct 2026 · Actual
- Status last verified
- Jun 2026
Primary outcomes (2)
Adverse events
Incidence and severity of treatment-emergent Adverse Events (AEs) and serious AEs and clinically significant changes in laboratory values, ECGs and vital signs
Time frame: Up to 5 years
Dose limiting toxicities
Number of participants with dose limiting toxicities
Time frame: 21 days
Secondary outcomes (6)
Drug concentrations over time
Observed blood concentration of each drug as applicable per subprotocol
Time frame: Up to 21 weeks
Cmax
Maximum observed blood concentration of each drug as applicable per subprotocol
Time frame: Up to 21 weeks
Tmax
Time to reach maximum blood concentration of each drug as applicable per subprotocol
Time frame: Up to 21 weeks
AUC
Area under the concentration-time curve of each drug as applicable per subprotocol
Time frame: Up to 21 weeks
ORR
Objective Response Rate per RECIST v1.1
Time frame: Up to 5 years
DOR
Duration of Response per RECIST v1.1
Time frame: Up to 5 years
STUDY TEAM
Sponsor and contacts
- Lead sponsor
- Revolution Medicines, Inc.
- Sponsor type
- Industry
- Collaborators
- Not reported
- Organisation study ID
- RMC-LUNG-101
Central study contacts
Study officials
Revolution MedicinesStudy director · Revolution Medicines
Contacts are provided by the registry for study enquiries. Do not use these details for marketing or promotions.
FURTHER READING
Results, documents and references
No results are posted in this registry record
This does not mean the study has no findings. Results may not yet have been submitted or published here.
No study documents are listed in this record.
Publications (1)
- Cregg J, Edwards AV, Chang S, Lee BJ, Knox JE, Tomlinson ACA, Marquez A, Liu Y, Freilich R, Aay N, Wang Y, Jiang L, Jiang J, Wang Z, Flagella M, Wildes D, Smith JAM, Singh M, Wang Z, Gill AL, Koltun ES. Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers. J Med Chem. 2025 Mar 27;68(6):6064-6083. doi: 10.1021/acs.jmedchem.4c02314. Epub 2025 Mar 8. PubMed ↗